Skip to content
DataLookout
Menu

NCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 83 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 49 words
    • Trial sites expanded: 314 → 317 locations
    • Secondary endpoints: details revised at 7 of 8 entries
  2. Minor Site details revised at 3 of 314 sites
  3. Minor Trial sites expanded: 311 → 314 locations
  4. Minor Site details revised at 1 of 311 sites
  5. Notable Eligibility criteria expanded, about 36 words
    • Study sites: 310 to 311
    • Secondary endpoints: details revised at 4 of 8 entries
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Study sites revised (310)v77
  2. Minor Study sites: 309 to 310v76
  3. Minor Study sites: 308 to 309v75
  4. Minor Site details revised at 1 of 308 sitesv74
  5. Minor Study sites: 307 to 308v73
  6. Minor Study sites: 306 to 307v72
  7. Minor Study sites: 305 to 306v71
  8. Minor Study sites: 304 to 305v70
  9. Minor Study sites: 303 to 304v69
  1. Minor Trial sites expanded: 299 → 303 locationsv68
  2. Minor Study sites: 297 to 299v67
  3. Minor Trial sites expanded: 293 → 297 locationsv66
  4. Minor Study sites: 292 to 293v65
  5. Minor Trial sites expanded: 288 → 292 locationsv64
  6. Minor Study sites: 287 to 288v63
  7. Minor Study sites: 286 to 287v62
  8. Minor Study sites: 285 to 286v61
  9. Minor Study sites: 284 to 285v60
  10. Minor Study sites: 281 to 284v59
  11. Minor Study sites: 280 to 281v58
  12. Minor Study sites: 279 to 280v57
  13. Minor Site details revised at 2 of 279 sitesv56
  14. Minor Study sites: 276 to 279v55
  15. Minor Study sites: 275 to 276v54
  16. Minor Study sites: 272 to 275v53
  17. Minor Study sites: 271 to 272v52
  18. Minor Study sites: 270 to 271v51
  19. Minor Study sites: 266 to 270v50
  20. Minor Study sites revised (266)v49
  21. Minor Study sites: 263 to 266v48
  22. Minor Study sites: 262 to 263v47
  23. Minor Study sites revised (262)v46
  24. Minor Study sites: 258 to 262v45
  25. Minor Study sites: 255 to 258v44
  26. Minor Study sites: 252 to 255v43
  27. Minor Study sites: 251 to 252v42
  28. Minor Study sites: 248 to 251v41
  29. Minor Study sites: 245 to 248v40
  30. Minor Study sites: 242 to 245v39
  31. Minor Site details revised at 2 of 242 sitesv38
  32. Minor Study sites: 240 to 242v37
  33. Minor Site contacts updated at 2 of 240 sitesv36
  34. Minor Study sites: 236 to 240v35
  35. Minor Site contacts updated at 1 of 236 sitesv34
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Invasive Disease-Free Survival (iDFS)
Timeframe: Up to approximately 77 months

Secondary (8)

Overall Survival (OS)
Distant recurrence-free survival (DRFS)
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Show 3 moreShow less
Change from baseline in EORTC QLQ-C30 Fatigue (Items 10, 12, and 18) Combined Score
Number of participants who experience one or more adverse events (AEs)
Number of participants who discontinue study intervention due to an AE

Arms and interventions

Pembrolizumab + sacituzumab tirumotecanExperimental

Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.

Treatment of Physician's ChoiceActive comparator

Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \[BID\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \[2 weeks 1, 1 week off\]) for 24 weeks.

Biologicals: Pembrolizumab, Sacituzumab tirumotecan

Drugs: Capecitabine

Sites

317 sites in 31 countries

United States 94, Japan 26, Germany 19, Canada 18, France 18, Italy 14, Spain 10, Poland 9, Brazil 8, Argentina 7, United Kingdom 7, Czechia 6, Denmark 6, Greece 6, Israel 6, Mexico 6, Sweden 6, Austria 5, South Korea 5, Switzerland 5, Turkey (Türkiye) 5, Australia 4, Colombia 4, Finland 4, Portugal 4, Belgium 3, Hong Kong 3, Ireland 3, Norway 3, Malaysia 2, Singapore 1